-
Pantsar T. The current understanding of KRAS protein structure and dynamics[J/OL]. Comput Struct Biotechnol J, 2020, 18: 189-198[2021-03-02]. https://www.sciencedirect.com/science/article/pii/S2001037019304647. DOI : 10.1016/j.csbj.2019.12.004.
-
Wu H Z, Xiao J Q, Xiao S S, et al. KRAS: a promising therapeutic target for cancer treatment[J]. Curr Top Med Chem, 2019, 19(23): 2081-2097.
-
Ward P S, Thompson C B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate[J]. Cancer Cell, 2012, 21(3): 297-308.
-
Koppenol W H, Bounds P L, Dang C V. Otto Warburg’s contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11(5): 325-337.
-
Pavlova N N, Thompson C B. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47.
-
Vander Heiden M G, DeBerardinis R J. Understanding the intersections between metabolism and cancer biology[J]. Cell, 2017, 168(4): 657-669.
-
Pupo E, Avanzato D, Middonti E, et al. KRAS-driven metabolic rewiring reveals novel actionable targets in cancer[J/OL]. Front Oncol, 2019, 9: 848[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/31544066/. DOI: 10.3389/fonc.2019.00848.
-
Hingorani S R, Petricoin E F, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse[J]. Cancer Cell, 2003, 4(6): 437-450.
-
Hingorani S R, Wang L, Multani A S, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice[J]. Cancer Cell, 2005, 7(5): 469-483.
-
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors[J]. Cancer Cell, 2020, 37(4): 543-550.
-
Hainsworth J D, Cebotaru C L, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens[J]. J Thorac Oncol, 2010, 5(10): 1630-1636.
-
Mirzoeva O K, Collisson E A, Schaefer P M, et al. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma[J]. Mol Cancer Ther, 2013, 12(10): 2213-2225.
-
Nagasaka M, Li Y, Sukari A, et al. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne[J/OL]. Cancer Treat Rev, 2020, 84: 101974[2021-03-02] . https://www.sciencedirect.com/science/articl e/abs/pii/S0305737220300128. DOI: 10.1016/
j.2020.101974.
-
Kerr E M, Gaude E, Turrell F K, et al. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities[J].Nature, 2016, 531(7592): 110-113.
-
Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in KRAS-driven cancers[J]. Int J Clin Oncol, 2017, 22(4): 651-659.
-
Humpton T J, Alagesan B, DeNicola G M, et al. Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer[J].Cancer Discov, 2019, 9(9): 1268-1287.
-
Lee A Y L, Dubois C L, Sarai K, et al. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma[J].Gut, 2019, 68(3): 487-498.
-
Ying H, Kimmelman A C, Lyssiotis C A, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism[J]. Cell, 2012, 149(3): 656-670.
-
Collins M A, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice[J]. J Clin Invest, 2012, 122(2): 639-653.
-
Dall’Olio F, Malagolini N, Trinchera M, et al. Mechanisms of cancerassociated glycosylation changes[J]. Front Biosci, 2012, 17(1): 670-699.
-
Gaglio D, Metallo C M, Gameiro P A, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth[J/OL]. Mol Syst Biol, 2011, 7(1): 523[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/21847114/. DOI:10.1038/msb.2011.56.
-
Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells[J]. Science, 2009, 325(5947): 1555-1559.
-
Miles K A, Ganeshan B, Rodriguez-Justo M, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer[J]. J Nucl Med, 2014, 55(3): 386-391.
-
Nagarajan A, Dogra S K, Sun L, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport[J]. Mol Cell, 2017, 67(4): 685-701.
-
Moldogazieva N T, Mokhosoev I M, Terentiev A A. Metabolic heterogeneity of cancer cells: an interplay between HIF-1, GLUTs, and AMPK[J/OL]. Cancers, 2020, 12(4): 862[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/32252351/. DOI: 10.3390/cancers12040862.
-
Planchard D, Besse B, Groen H J M, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial[J].Lancet Oncol, 2016, 17(7): 984-993.
-
Rinehart J, Adjei A A, Lorusso P M, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-smallcell lung, breast, colon, and pancreatic cancer[J]. J Clin Oncol, 2004, 22(22): 4456-4462.
-
Pant S, Bendell J C, Sullivan R J, et al. A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts)[J/OL]. J Clin Oncol, 2019, 37(15_suppl): 3001[2021-03-02]. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3001.
-
Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(3): 153-168.
-
Bott A J, Shen J, Tonelli C, et al. Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism [J]. Cell Rep, 2019, 29(5): 1287-1298.
-
Son J, Lyssiotis C A, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway[J].Nature, 2013, 496(7443): 101-105.
-
Lyssiotis C A, Son J, Cantley L C, et al. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance[J].Cell Cycle, 2013, 12(13): 1987-1988.
-
Viale A, Pettazzoni P, Lyssiotis C A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function[J]. Nature, 2014, 514(7524): 628-632.
-
DeNicola G M, Karreth F A, Humpton T J, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis[J].Nature, 2011, 475(7354): 106-109.
-
Dey P, Li J, Zhang J, et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment[J]. Cancer Discov, 2020, 10(4): 608-625.
-
Gaglio D, Bonanomi M, Valtorta S, et al. Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors as revealed by metabolic connectivity profiling[J]. Cancer Metab, 2020, 88(1): 22[2021-03-02]. http://pubmed. ncbi.nlm.nih.gov/33005401/.DOI: 10.1186/s40170-020-00227-4.
-
Nwosu Z C, Piorońska W, Battello N, et al. Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance[J]. EBioMedicine, 2020, 54(3): 42[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/32330875/. DOI: 10.1016/j.ebiom.2020.102699.
-
Kimmelman A C. The dynamic nature of autophagy in cancer[J].Genes Dev, 2011, 25(19): 1999-2010.
-
Bryant K L, Stalnecker C A, Zeitouni D, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer [J]. Nat Med, 2019, 25(4): 628-640.
-
Yang Z, Klionsky D J. Eaten alive: a history of macroautophagy[J].Nat Cell Biol, 2010, 12(9): 814-822.
-
Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein[J]. Autophagy, 2020, 16(11): 2069-2083.
-
Rogov V, Dötsch V, Johansen T, et al. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy[J]. Mol Cell, 2014, 53(2): 167-178.
-
Schreiber A, Peter M. Substrate recognition in selective autophagy and the ubiquitin-proteasome system[J]. Biochim Biophys Acta, 2014, 1843(1): 163-181.
-
Wolpin B M, Rubinson D A, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma[J]. Oncologist, 2014, 19(6): 637-638.
-
Goldberg S B, Supko J G, Neal J W, et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer[J]. J Thorac Oncol, 2012, 7(10): 1602-1608.
-
Egan D F, Chun M G, Vamos M, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates[J].Mol Cell, 2015, 59(2): 285-297.
-
Martin K R, Celano S L, Solitro A R, et al. A potent and selective ULK1 inhibitor suppresses autophagy and sensitizes cancer cells to nutrient stress[J/OL]. iScience, 2018, 8: 74-84[2021-03-02]. https://pubmed.ncbi.nlm.nih.gov/30292171/. DOI: 10.1016/j.isci.2018.09.012.
-
Guo J, Zhang J, Liang L, et al. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin[J]. J Cell Mol Med, 2020, 24(7): 4324-4340.
-
Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia[J].Int J Oncol, 2014, 44(5): 1661-1668.
-
Nawrocki S T, Wang W, Carew J S. Autophagy: new insights into its roles in cancer progression and drug resistance[J/OL]. Cancers, 2020, 2(10): 3005[2021-03-02]. https://pubmed.ncbi.nlm. nih.gov/33081217/. DOI: 10.3390/cancers12103005.
-
Carew J S, Nawrocki S T. Drain the lysosome: development of the novel orally available autophagy inhibitor ROC-325[J]. Autophagy, 2017, 13(4): 765-766.
-
Zhang X J, Chen S, Huang K X, et al. Why should autophagic flux be assessed? [J]. Acta Pharmacol Sin, 2013, 34(5): 595-599.
-
Bar-Sagi D, Feramisco J R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins[J]. Science, 1986, 233(4768): 1061-1068.
-
Yoshida S, Pacitto R, Inoki K, et al. Macropinocytosis, mTORC1 and cellular growth control[J]. Cell Mol Life Sci, 2018, 75(7): 1227-1239.
-
Liu H, Sun M, Liu Z, et al. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs[J/OL]. J Controlled Release, 2019, 296: 40-53[2021-03-02]. https://www.sciencedirect.com/science/article/abs/pii/S016836591930032X. DOI: 10.1016/j.jconrel.2019.01.014.
-
Lim J P, Gleeson P A. Macropinocytosis: an endocytic pathway for internalising large gulps[J]. Immunol Cell Biol, 2011, 89(8): 836-843.
-
Kamphorst J J, Cross J R, Fan J, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids[J]. Proc Natl Acad Sci USA, 2013, 110(22): 8882-8887.
-
Von Hoff D D, Ervin T, Arena F P, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18): 1691-1703.
-
Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer[J]. Nat Rev Cancer, 2016, 16(11): 732-749.
-
Padanad M S, Konstantinidou G, Venkateswaran N, et al. Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis[J]. Cell Rep, 2016, 16(6): 1614-1628.
-
Singh A, Ruiz C, Bhalla K, et al. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer[J]. FASEB J, 2018, 32(12): fj201800204[2021-03-02]. http://pubmed.ncbi.nlm. nih.gov/29906244/. DOI: 10.1096/fj.201800204.
-
Patra K C, Kato Y, Mizukami Y, et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism[J]. Nat Cell Biol, 2018, 20(7): 811-822.
-
Gouw A M, Eberlin L S, Margulis K, et al. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma[J]. Proc Natl Acad Sci USA, 2017, 114(17): 4300-4305.
-
Dias Carvalho P, Machado A L, Martins F, et al. Targeting the tumor microenvironment: an unexplored strategy for mutant KRAS tumors[J/OL]. Cancers, 2019, 11(12): 2010[2021-03-02]. http://pubmed.ncib.nlm.gov/31847069/. DOI: 10.3390/cancers11122010.